MATTHEW E FEIL

Allopathic & Osteopathic Physicians|Emergency Medicine WEST VALLEY CITY, UT NPI 1790745271

General Payments — all program years on this page

$196,088.71

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 102
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $66,048.02 across 30 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $66,033.4329
Food and Beverage $14.591

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $66,033.4329
PFIZER INC. $14.591

By program year

Program yearAmountRecords
2018 $11.561
2019 $32.142
2020 $15,332.4310
2021 $28,166.7113
2022 $50,590.5827
2023 $35,907.2719
2024 $66,048.0230

Records — PY2024 (30)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1131898949 PFIZER INC. $14.59 08/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137544943 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544947 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544951 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544955 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544959 Takeda Pharmaceuticals U.S.A., Inc. $2,166.67 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544963 Takeda Pharmaceuticals U.S.A., Inc. $2,166.67 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544967 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544971 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544975 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544979 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544983 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544987 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544990 Takeda Pharmaceuticals U.S.A., Inc. $2,166.67 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544994 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137544998 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545001 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545005 Takeda Pharmaceuticals U.S.A., Inc. $2,166.67 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545009 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545013 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545017 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545021 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545025 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545029 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545033 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545037 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545041 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545045 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545049 Takeda Pharmaceuticals U.S.A., Inc. $2,266.67 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137545053 Takeda Pharmaceuticals U.S.A., Inc. $2,366.67 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.